Table 3 Dose fractionation schedules of randomized trials of WBRT alone
From: Neuropsychological testing and biomarkers in the management of brain metastases
Study (ref) | Year | n | (Gy)/number of fractions | Median Survival (months) |
|---|---|---|---|---|
Harwood et al [14] | 1977 | 101 | 30/10 vs 10/1 | 4.0–4.3 |
Kurtz et al [15] | 1981 | 255 | 30/10 vs 50/20 | 3.9–4.2 |
Borgelt et al [4] | 1980 | 138 | 10/1 vs 30/10 vs 40/20 | 4.2–4.8 |
Borgelt et al [16] | 1981 | 64 | 12/2 vs 20/5 | 2.8–3.0 |
Chatani et al [17] | 1986 | 70 | 30/10 vs 50/20 | 3.0–4.0 |
Haie-Meder et al [18] | 1993 | 216 | 18/3 vs 36/6 or 43/13 | 4.2–5.3 |
Chatani et al [19] | 1994 | 72 | 30/10 vs 50/20 or 20/5 | 2.4–4.3 |
Murray et al [20] | 1997 | 445 | 54.4/34 vs 30/10 | 4.5 |